Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-01-09
2007-01-09
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S387300, C530S388220, C530S391700
Reexamination Certificate
active
09945265
ABSTRACT:
The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. Modified integrin I-domain polypeptides that are stabilized in a desired conformation are also provided. Finally, screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention are also provided.
REFERENCES:
patent: 5284931 (1994-02-01), Springer et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5395929 (1995-03-01), Corbi et al.
patent: 5460945 (1995-10-01), Springer et al.
patent: 5475091 (1995-12-01), Springer et al.
patent: 5489533 (1996-02-01), Springer et al.
patent: 5512660 (1996-04-01), Springer et al.
patent: 5514555 (1996-05-01), Springer et al.
patent: 5565550 (1996-10-01), Springer et al.
patent: 5599676 (1997-02-01), Vonderheide et al.
patent: 5612216 (1997-03-01), Springer et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5629162 (1997-05-01), deFougerolles et al.
patent: 5686265 (1997-11-01), Corbi et al.
patent: 5739032 (1998-04-01), Springer et al.
patent: 5747035 (1998-05-01), Presta et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5831036 (1998-11-01), Springer et al.
patent: 5843712 (1998-12-01), Levine
patent: 5849896 (1998-12-01), Springer et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5877295 (1999-03-01), Diamond et al.
patent: 5891841 (1999-04-01), deFougerolles et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 5948758 (1999-09-01), Springer et al.
patent: 6030947 (2000-02-01), Corbi et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: 6121428 (2000-09-01), Blank et al.
patent: 6358510 (2002-03-01), Springer et al.
patent: 6413963 (2002-07-01), Kahn et al.
patent: 6436403 (2002-08-01), Springer et al.
patent: 6511664 (2003-01-01), Springer et al.
patent: 6528599 (2003-03-01), Nobori et al.
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6683158 (2004-01-01), Springer et al.
patent: 6777191 (2004-08-01), Springer et al.
patent: 6797270 (2004-09-01), Springer et al.
patent: 2001/0031260 (2001-10-01), Lee et al.
patent: 2003/0054440 (2003-03-01), Mayo et al.
patent: 440 351 (1991-08-01), None
patent: WO 94/04188 (1994-03-01), None
patent: WO 95/17412 (1995-06-01), None
Huang et al. Folding of the beta-propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the beta2 subunit. Proc Natl Acad Sci U S A. 94(7):3162-7, 1997.
Lu et al. Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci U S A. 98(5):2393-8, 2001.
Owens, RJ, Young RJ. The genetic engineering of monoclonal antibodies. J Immunol Methods. 168(2):149-165, 1994.
Bost KL, Pascual DW. Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2. Immunol Invest. 17(6-7):577-86, 1988.
Bajt, J.L. et al,Characterization of a gain of function mutation of integrin alpha Ilb beta 3(platelet glycoprotein Ilb-IIIa), J. Biol. Chem. Nov. 5, 1992, vol. 267, No. 31, pp. 22211-22216 (1992).
Salas, A., et al.,Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lymphocyte function-associated antigen-I. J. Biol. Chem. Dec. 27, 2002, vol. 277, No. 52, pp. 50255-50262 (2002).
Takagi, J., et al.,Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. Sep. 6, 2002, vol. 110, No. 5, pp. 599-611 (2002).
Oxvig et al.,Conformational changes in tertiary structure near the ligand binding site of an integrin I domain., PNAS, 96: 2215-2200 (1999).
Landis, et al. ,Involvement of the “I” Domain of the LFA-1 in Selective Bnding to Ligands ICAM-I and ICAM-3, J. Cell. Biol., 126:529-537 (1994).
Landis et al. ,A Novel LFA-I Activation Epitope Maps to the I Domain, J. Cell. Biol., 120:1519-1527 (1993).
Larson et al.,Primary Structure of the Leukocyte Function-associated Molecule 1β Subunit: an Integrin with an Embedded Domain Defining a ProteinSuperfamily, J. Cell Biol., 108:703-712 (1989).
Dransfield et al.,Interaction of Leukocyte Integrins with Ligand Is Necessary but Not Sufficient for Function, J. Cell. Biol., 116:1527-1535 (1992).
Bullard et al.,A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice, PNAS, 93: 2116-2121 (1996).
Huang et al.,A Binding Interface on the I Domain of Lymphocyte Function-associated Antigen-I(LFA-I)Required for Specific Interaction with Intercellular Adhesion molecule 1(ICAM-I), J. Biol. Chem, 270:19008-19016 (1995).
Dransfield et al,Divalent Cation Regulation of the Function of the Leukocyte Integrin LFA-I, J. Cell Biol., 116:219-226 (1992).
Champe et al.,Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen I Recognize Three Discrete Epitopes in the Inserted Domain of CA11a, J. Bio.; Chem., 270:3 1388-1394 (1995).
Kooyk et al.,Activation of LFA-I through the Ca2+-dependent Epitope Stimulates Lymphocyte Adhesion, J. Cell Biol., 112:345-354 (1991).
Keizer et al.,A Monoclonal Antibody(NKI-L16)Directed against a Unique Epitope on the β-chain of Human Leukocyte Function Associated Antigen I. . . , J. Immunol 140:1393 (1988).
Qu et al.,Crystal structure of the I-domain from the CDIIa/CD18(LFA-I. βα2)Integrin, PNAS, 92:10277-10281 (1995).
“National PBM Drug Monograph Efalizumab,” www.vapbm.org p. 1-25 (Feb. 2004).
Dickeson SK et al. Ligand recognition by the I domain-containing integrins. Cell Mol Life Sci. Jun. 1998;54(6):556-66.
Hazes, B et al. Model building of disulfide bonds in proteins with known three-dimensional structure.Protein Eng. Jul. 1988;2(2):119-25.
Huth, J et al. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc Natl Acad Sci U S A. May 9, 2000;97(10):5231-6.
Larson RS, et al. Primary structure of the leukocyte function-associated molecule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily J Cell Biol. Feb. 1989;108(2):703-12.
Lee, Jie-Oh et al. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell. Feb. 24, 1995;80(4):631-8.
Lee, Jie-Oh et al Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. Dec. 15, 1995;3(12):1333-40.
Leitinger B, et al. The regulation of integrin function by Ca(2+ ). Biochim Biophys Acta. Dec. 20, 2000;1498(2-3):91-98.
Li, Rui et al. Two functional states of the CD11b A-domain: correlations with key features of two Mn2+-complexed crystal structures. J Cell Biol. Dec. 14, 1998;143(6):1523-34.
Lu, C et al. An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc Natl Acad Sci U S A. Feb. 27, 2001;98(5):2387-92.
Lu, C et al. Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci U S A. Feb. 27, 2001;98(5):2393-8.
Ohashi Y, et al. Three monoclonal antibodies against human LFA-1 alpha and beta chains with different biological activities. Tohoku J Exp Med. Dec. 1992;168(4):599-610.
Orchekowski RP, et al. AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive. J Leukoc Biol. Nov. 2000;68(5):641-9.
Oxvig, C et al. Conformational changes in tertiary structure near the ligand binding site of an int
Lu Chafen
Shimaoka Motomu
Springer Timothy A.
Gosz & Partners LLP
Haddad Maher M.
The Center for Blood Research, Inc.
LandOfFree
Modified polypeptides stabilized in a desired conformation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified polypeptides stabilized in a desired conformation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified polypeptides stabilized in a desired conformation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731369